A New Sticky Sealant Is Healing Dog Eye Ulcers in Under Four Days. What a Konkuk University Trial Means for Your Vet's Toolkit.

If you have ever watched your dog squint, paw at their face, and tear up out of one eye, you already know how fast a corneal ulcer becomes the worst part of your week. They are common. They are painful. And the standard medical treatment, eye drops on a strict schedule plus a cone of shame, can drag out for a week or more while you and the dog both lose sleep. A new study published this month suggests the recovery side of that picture might be about to get meaningfully shorter.

The paper is Yang et al., "Novel Non-Invasive Treatment for Canine Corneal Ulcers: Application of New Extracellular Matrix-Based Sticky Sealants," published in Veterinary Ophthalmology in May 2026 (DOI: 10.1111/vop.70181, PMID 41969020). The work was a collaboration between the Department of Veterinary Ophthalmology at Konkuk University in Seoul, Biobricks Co., Ltd. (a regenerative biomaterials company), and the mechanical engineering team at the Pohang University of Science and Technology, known as POSTECH.

The team enrolled 60 eyes from 56 client-owned dogs diagnosed with stromal ulcerative keratitis. Stromal ulcers are the middle-layer kind, deeper than a simple surface scratch but not yet a full perforation. They are the cases where most general-practice vets weigh whether to keep treating medically or refer to a specialist for surgical intervention. The study capped enrollment at ulcers covering less than 50 percent of corneal thickness, so this was a moderate-severity population, not the worst cases.

Half the eyes (30) received a new gelatinized cornea-derived decellularized extracellular matrix (the authors call it Cod-ECM) on top of standard medical therapy. The other half received standard medical therapy alone. The study tracked corneal opacity using a semi-quantitative preclinical ocular toxicology score, measured corneal blood-vessel growth (neovascularization), and timed how long it took for each eye to fully close the wound.

Both groups eventually achieved complete re-epithelialization, which is the medical phrase for "the surface healed over." That part is the good news in either treatment arm.

Where the new sealant separated from the standard-care group was the speed of healing and the clarity of the cornea after healing. Eyes treated with the gelatinized Cod-ECM sealant healed in 3.9 days plus or minus 0.7, compared to 5.3 days plus or minus 1.0 in the control group, with the difference statistically significant at p less than 0.01. The sealant group also showed significantly less corneal opacity at follow-up, which matters because lingering opacity is what compromises long-term vision after even a "successful" ulcer treatment.

One thing the sealant did not do better than standard care: corneal blood-vessel growth. Neovascularization scores were similar in both groups (p equals 0.3). The authors are appropriately direct about this. The sealant accelerates surface healing and improves clarity. It does not appear to change the vessel-recruitment side of the wound response.

A few practical points if your dog has had a corneal ulcer or is in a breed at higher risk (Boston Terriers, Pugs, Shih Tzus, Bulldogs, and other brachycephalic breeds where prominent eyes meet shorter snouts).

First, a 1.4-day reduction in healing time is not a marketing number, it is a real-world quality-of-life improvement. Less time in the cone, fewer drops on a strict schedule, fewer follow-up visits, less time the dog is in pain. For a working family or a multi-pet household, that is the difference between a manageable inconvenience and a week of disrupted sleep for everyone.

Second, the clarity outcome matters more than the speed outcome over the long run. Corneal scarring after an ulcer can subtly affect a dog's vision for life, especially if the scar sits in the central visual axis. The Yang et al. data suggest the new sealant may leave a clearer cornea behind, which is the kind of secondary endpoint that compounds in value as the dog ages.

Third, this is not yet at your local vet clinic. The study was a clinical trial published in a peer-reviewed journal, not a product launch. Biobricks has the technology, and Konkuk has the clinical data, but the regulatory pathway from this kind of result to commercial veterinary use is measured in years, not weeks. The right next questions are which markets this enters first, whether the FDA Center for Veterinary Medicine treats this as a device or a biologic, and whether the larger ophthalmology distributors will pick it up.

The study had 60 eyes from 56 dogs, which is a reasonable size for a single-center proof-of-concept trial but is not enough to declare the approach broadly safe and effective across breeds and ulcer types. Larger multi-center trials are still needed, and the published data does not yet include longer follow-up to see whether late-stage scarring or recurrence rates differ between the two arms.

The exclusion of ulcers covering more than 50 percent of corneal thickness is also worth flagging. Severe and deep ulcers, the ones most likely to need a corneal transplant or conjunctival graft, were not part of this study. Whether the sealant accelerates healing in those tougher cases or whether it is contraindicated, we do not yet know.

Pancake, my Labrador, came home from a beach weekend last summer with a small surface scratch on her left eye. Two days of pawing later, what had been a minor irritation was a full surface ulcer, and we were on the schedule for an emergency ophthalmology consult. Her case healed without complications on conventional therapy, but the eight-day total recovery window included two trips back to the clinic, three weeks of restricted activity, and one episode of a removed cone followed immediately by more pawing. If a topical sealant could have shaved the active treatment window from eight days to six, that would have been worth a meaningful premium to me, and I suspect it would be to most of you too.

If you find yourself in this situation in the next year or two, the questions worth asking a veterinary ophthalmologist are: how deep is the ulcer (surface, stromal, or descemetocele); how aggressive is the medical therapy plan; and whether any of the newer extracellular-matrix-based products are available locally yet. Most ophthalmologists are tracking this category and will tell you frankly whether the technology has reached your region.

The real signal here is not just the Cod-ECM result. It is that veterinary ophthalmology is increasingly publishing trials with the kind of comparative arms and statistical reporting that human medicine treats as table stakes. That is the part of the field worth watching, because the rest of veterinary medicine will follow it.

If your dog has ever pawed at a cone for forty-eight hours straight, you already know that "less time in the cone" is the most important medical endpoint nobody puts in the abstract.